Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05537233 · ClinicalTrials.gov registry record · Phase 2
ADJUnct Semaglutide Treatment in Type 1 Diabetes
A Phase 2 study of Obesity and Type 1 Diabetes, sponsored by Viral N. Shah.
- Completed
- Registry status
- Phase 2
- Development phase
- 115
- Enrollment target
- 4
- Study locations
NCT05537233: Completed Phase 2 study of Obesity and Type 1 Diabetes, sponsored by Viral N. Shah.
NCT05537233 is a Phase 2 study of Obesity and Type 1 Diabetes that has completed, run by Viral N. Shah. The registered enrollment target is 115 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (86% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05537233, a Phase 2 study of Obesity and Type 1 Diabetes, has completed, sponsored by Viral N. Shah.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 115 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to assess the use of once weekly semaglutide injection in inadequately controlled obese adults with type 1 diabetes (T1D) using FDA-approved hybrid closed-loop therapies.
Primary Outcome
Primary outcome will be analyzed per statistical analysis plan using intention to treat basis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Semaglutide
Study Locations (4)
Colorado
- Barbara Davis Center for Diabetes - Aurora
Iowa
- Iowa Diabetes Research Center - West Des Moines
Michigan
- Henry Ford Hospital - Detroit
Oregon
- Harold Schnitzer Diabetes Health Center - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2023-04-11 |
| Est. Completion | 2024-08-06 |
| Phase | Phase 2 |
What the finished NCT05537233 record still lists
NCT05537233 is an interventional study that assigns participants to a tested intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (86% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05537233 reports a single indexed study location in Colorado, Iowa, Michigan.
Frequently Asked Questions
What is clinical trial NCT05537233 about?
NCT05537233 is a clinical study titled "ADJUnct Semaglutide Treatment in Type 1 Diabetes". The purpose of this study is to assess the use of once weekly semaglutide injection in inadequately controlled obese adults with type 1 diabetes (T1D) using FDA-approved hybrid closed-loop therapies.
What is the current status of trial NCT05537233?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 115 participants. The study started on 2023-04-11. Estimated completion is 2024-08-06.
What conditions does trial NCT05537233 study?
This clinical trial studies the following conditions: Obesity, Type 1 Diabetes.
What interventions are being tested in trial NCT05537233?
The interventions under investigation include: Placebo (DRUG), Semaglutide (DRUG).
Who is sponsoring clinical trial NCT05537233?
This trial is sponsored by Viral N. Shah, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05537233 being conducted?
This trial has 4 study locations across Colorado, Iowa, Michigan, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05537233's enrollment target sits among peer trials
115 450th of 1053 higher than 602 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02346929 · 115 participants · NA
Hematoma Block for Distal Radius Fracture
- NCT03394365 · 115 participants · Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- NCT03907475 · 115 participants · Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- NCT05086692 · 115 participants · Phase 1
A Beta-only IL-2 ImmunoTherapY Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI